ASH 2017 | Next steps in VTE treatment: will oral edoxoban replace the current standard of care?

Harry Buller

There was exciting news at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, with data from the Hokusai venous thromboembolism (VTE)-Cancer Study (NCT02073682) presented as a late-breaking abstract. Here, Harry Buller, MD, PhD, of the Academic Medical Centre, Amsterdam, Netherlands, discusses whether oral edoxoban could become the new standard of care for cancer-associated VTE. Prof. Buller also shares his predictions on the future of VTE treatment following the success of the Hokusai VTE-Cancer Study.

Share this video